Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01003678|
Recruitment Status : Terminated (Drug provider withdrew support)
First Posted : October 29, 2009
Last Update Posted : June 3, 2016
This is a Phase I trial for patients with intermediate or high risk myelodysplastic syndrome (MDS).
The study agent, clofarabine, is produced by Genzyme Pharmaceuticals.
|Condition or disease||Intervention/treatment||Phase|
|Myelodysplastic Syndrome||Drug: Clofarabine||Phase 1|
The specific purpose of the study is to determine the safety, maximum tolerated dose (MTD) and recommended Phase II dose of clofarabine in patients with MDS.
- We will start at a dose of 1 mg daily.
- We will treat a group of 3 patients with clofarabine at that dose level.
- If there are no severe side effects seen at that dose level, then the next group of 3 patients will receive a higher dose.
- Treatment of groups of 3 patients will continue at higher dose levels until severe side-effects are noted.
- If more than 1 of the 3 patients experiences a severe side effect, dosing will be stopped at that level.
- If only one of the three patients experience a severe side effect, then three more patients will be treated, at that dose level and if they too experience severe side effects, then dose escalation will be stopped and the maximum tolerated dose will be determined.
- 10 more patients will be enrolled at the maximum tolerated dose.
- There will be up to 5 dose levels tested.
- We plan to test how much of the drugs are in the patient's blood at different times, and the levels of certain proteins in their blood.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||4 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase I Study Evaluating the Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients|
|Study Start Date :||October 2009|
|Primary Completion Date :||June 2013|
|Study Completion Date :||October 2013|
Experimental: Level 1
1 mg daily for 5 consecutive days followed by 23 days off drug
Dose Escalation Schedule - Level 1: 1 mg daily x 5 days (orally) followed by 23 days off drug.
Levels 2, 3, 4 and 5 are: 3, 5, 10 and 15 mg daily x 5 days followed by 23 days off drug.
- To determine the safety, maximum tolerated dose (MTD) and recommended phase II dose of Clofarabine in patients with myelodysplastic syndrome (MDS). [ Time Frame: Up to 6 months ]
- To determine the efficacy of Clofarabine in patients with MDS [ Time Frame: Up to 6 months ]
- To determine the differences in clofarabine triphosphate levels in cells following clofarabine treatment [ Time Frame: Pre, Day 1: Hourly for 6 hours, Pre Day 5:Hourly for 5 hours ]
- Determine the differences in clofarabine plasma levels following clofarabine treatment [ Time Frame: Pre, Day 1: Hourly for 6 hours, Pre Day 5:Hourly for 5 hours ]
- Evaluate the effect of clofarabine on DNA methylation [ Time Frame: Pre and Day 1 ]
- Estimate post-treatment p53R2levels in patients treated at the MTD (in the expanded cohort) [ Time Frame: At 6 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01003678
|United States, New York|
|Roswell Park Cancer Institute|
|Buffalo, New York, United States, 14263|
|Principal Investigator:||Wetzler Meir, MD||Roswell Park Cancer Institute|